GHENT, BELGIUM--(Marketwire - January 21, 2013) - Ablynx (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 61,812 common shares have been issued by the Company in exchange for EUR 329,619.51 as the result of the exercise of warrants by some employees and consultants of the Company.
As a result of this transaction, Ablynx now has 43,779,197 shares outstanding.
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and five Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
Press release (PDF): http://hugin.info/137912/R/1671922/543522.pdf